| Followers | 19 |
| Posts | 1141 |
| Boards Moderated | 0 |
| Alias Born | 02/11/2011 |
Thursday, December 14, 2017 8:39:53 PM
Some quick things for the Board to think about that I have not seen come up:
1) Tax loss benefit. If a mature pharma is looking to acquire DCTH, there is value in the sizeable losses the company has racked up (reduce taxes payable on other products or future gains here).
2) Bankruptcy doesn't make sense. It's a big deal for a CEO. Usually, they can no longer serve as an executive.. at any company. And why would they? They just got rid of their liabilities.
3) Why did they get rid of their liabilities? I speculate they are prepping for a sale. Firstly it should remove any covenants in place that could kill a deal. Secondly, I expect people in the know have picked up sizeable positions out of the millions of shares dumped to payout the Lenders. Dumping shares allowed those in the know to build low cost positions and gain larger exposure to a run up on FDA approval, buyout spec, etc.
4) Who took up all these dumped shares? Do you think retail had the appetite to absorb the over $10MM pumped out in shares? Especially after the scary 350-1 RS? I doubt that. Most retail already got played here. No powder or too burned to buy more.
5) Fraud? Sorry, nothing here looks like fraud. Shareholders might not like the fact they lost a ton of money but equity shares are worth only what the open market values them at. The company used this fact to their advantage.
I still think this is highly speculative and anything can happen but worth establishing a position.
1) Tax loss benefit. If a mature pharma is looking to acquire DCTH, there is value in the sizeable losses the company has racked up (reduce taxes payable on other products or future gains here).
2) Bankruptcy doesn't make sense. It's a big deal for a CEO. Usually, they can no longer serve as an executive.. at any company. And why would they? They just got rid of their liabilities.
3) Why did they get rid of their liabilities? I speculate they are prepping for a sale. Firstly it should remove any covenants in place that could kill a deal. Secondly, I expect people in the know have picked up sizeable positions out of the millions of shares dumped to payout the Lenders. Dumping shares allowed those in the know to build low cost positions and gain larger exposure to a run up on FDA approval, buyout spec, etc.
4) Who took up all these dumped shares? Do you think retail had the appetite to absorb the over $10MM pumped out in shares? Especially after the scary 350-1 RS? I doubt that. Most retail already got played here. No powder or too burned to buy more.
5) Fraud? Sorry, nothing here looks like fraud. Shareholders might not like the fact they lost a ton of money but equity shares are worth only what the open market values them at. The company used this fact to their advantage.
I still think this is highly speculative and anything can happen but worth establishing a position.
Recent DCTH News
- Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts • Business Wire • 05/26/2026 08:01:00 PM
- Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 05/15/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:47:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 12:23:52 PM
- Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference • Business Wire • 05/12/2026 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 01:09:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 12:12:12 PM
- Delcath Systems Reports First Quarter 2026 Results and Business Highlights • Business Wire • 05/07/2026 12:00:00 PM
- Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026 • Business Wire • 05/07/2026 11:00:00 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/27/2026 08:12:24 PM
- Delcath Systems to Host First Quarter 2026 Earnings Call • Business Wire • 04/23/2026 12:30:00 PM
- Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma • Business Wire • 04/06/2026 12:30:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/02/2026 12:56:15 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/02/2026 12:55:31 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/02/2026 12:52:52 PM
- Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting • Business Wire • 04/01/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:22:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 09:48:16 PM
- Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology • Business Wire • 03/03/2026 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 02:15:35 PM
